Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays.

Reference standards for next-generation sequencing. Nat Rev Genet (2017) 0.77

Development and Characterization of Reference Materials for Genetic Testing: Focus on Public Partnerships. Ann Lab Med (2016) 0.75

The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39

Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38

ACMG clinical laboratory standards for next-generation sequencing. Genet Med (2013) 5.30

The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24

Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol (2014) 4.07

Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62

Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42

Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov (2015) 2.07

Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70

Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. J Mol Diagn (2012) 1.57

Next-generation sequencing in the clinic: promises and challenges. Cancer Lett (2012) 1.39

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun (2015) 1.33

Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12

Prioritizing targets for precision cancer medicine. Ann Oncol (2014) 1.06

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. J Mol Diagn (2015) 0.90

Recombination phenotypes of the NCI-60 collection of human cancer cells. BMC Mol Biol (2011) 0.87

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. J Mol Diagn (2015) 0.90

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clin Cancer Res (2015) 0.79

Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods. J Mol Diagn (2016) 0.79

Next-Generation Sequencing to Guide Clinical Trials. Clin Cancer Res (2015) 0.76

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn (2017) 0.75

A mutational comparison of adult and adolescent and young adult (AYA) colon cancer. Cancer (2017) 0.75